December 2016
-
AIM ImmunoTech has announced that it will definitely advance an intranasal formulation of its Ampligen rintatolimod into a Phase 2 trial after the initial dose tested in a Phase 1 study showed no safety problems.… Read more . . .
-
According to Teva Pharmaceuticals Europe, the company has received marketing authorization in the EU for duplicate DPIs Seffalair Spiromax salmeterol xinafoate/ fluticasone propionate and BroPair Spiromax salmeterol xinafoate/ fluticasone propionate for the treatment for asthma… Read more . . .
-
Intravacc has announced that a pre-clinical study of its intranasal outer membrane vesicle (OMV)-based recombinant spike protein (rSP) vaccine candidate against SARS-CoV-2 nose spray vaccine in hamsters and mice demonstrated complete protection. The company announced… Read more . . .
-
Kindeva Drug Delivery has partnered with Cambridge Healthcare Innovations (CHI) for development and commercialization of CHI’s Aeolus DPI platform, the company said. The Aeolus device is breath-activated, blister-based, and comes in single use, reusable, and… Read more . . .
-
Seelos Therapeutics has signed a strategic device partnership agreement with Aptar Pharma for the use of Aptar’s Bidose Liquid System (BDS) for Seelos’ SLS-002 intranasal ketamine, Seelos said. SLS-002 is in Phase 2 development for the… Read more . . .
-
According to Union Therapeutics, a Phase 1 study of its UNI911 niclosamide solution met its primary endpoint, demonstrating “a strong safety profile” for both inhaled and intranasal delivery; the company said that the PK results were… Read more . . .
-
Respirent has submitted an ANDA to the FDA for its fluticasone propionate / salmeterol xinafoate DPI in 100/50 μg, 250/50 μg, and 500/50 μg dose levels for the treatment of asthma and COPD, according to… Read more . . .
-
According to United Therapeutics, the FDA has approved Tyvaso treprostinil inhalation solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). Tyvaso has been approved for the treatment of pulmonary arterial hypertension… Read more . . .
-
According to Iconovo, Swedish immunotherapy developer Immune System Regulation (ISR) will pay up to 18.1 million Swedish kronor plus potential royalties for development of a dry powder COVID-19 vaccine delivered via Iconovo’s ICOone single dose… Read more . . .
-
Coster and Lindal have announced that they will each transfer their pharmaceutical aerosol businesses into a new company called RxPack, which will operate independently of both parent companies. RxPack will distribute Coster’s aerosol filling equipment… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK